- Home
- THAR vs KTTA Comparison
THAR vs KTTA Comparison
Compare THAR & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- KTTA
- Stock Information
- Founded
- THAR 2017
- KTTA 2020
- Country
- THAR United States
- KTTA United States
- Employees
- THAR N/A
- KTTA N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- KTTA Health Care
- Exchange
- THAR Nasdaq
- KTTA Nasdaq
- Market Cap
- THAR 5.5M
- KTTA 5.1M
- IPO Year
- THAR 2022
- KTTA 2021
- Fundamental
- Price
- THAR $3.68
- KTTA $0.79
- Analyst Decision
- THAR Strong Buy
- KTTA
- Analyst Count
- THAR 1
- KTTA 0
- Target Price
- THAR $17.00
- KTTA N/A
- AVG Volume (30 Days)
- THAR 29.2M
- KTTA 178.0K
- Earning Date
- THAR 11-06-2025
- KTTA 08-14-2025
- Dividend Yield
- THAR N/A
- KTTA N/A
- EPS Growth
- THAR N/A
- KTTA N/A
- EPS
- THAR N/A
- KTTA N/A
- Revenue
- THAR N/A
- KTTA N/A
- Revenue This Year
- THAR N/A
- KTTA N/A
- Revenue Next Year
- THAR N/A
- KTTA N/A
- P/E Ratio
- THAR N/A
- KTTA N/A
- Revenue Growth
- THAR N/A
- KTTA N/A
- 52 Week Low
- THAR $0.95
- KTTA $0.65
- 52 Week High
- THAR $9.08
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- THAR 50.85
- KTTA 54.58
- Support Level
- THAR $4.94
- KTTA $0.75
- Resistance Level
- THAR $7.25
- KTTA $0.91
- Average True Range (ATR)
- THAR 1.50
- KTTA 0.06
- MACD
- THAR -0.08
- KTTA 0.01
- Stochastic Oscillator
- THAR 32.49
- KTTA 45.79
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).